НЕХОДЖКИНСКИЕ ЛИМФОМЫ ПРИ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЯХ
https://doi.org/10.14412/1995-4484-2011-1464
Аннотация
Неходжкинские лимфомы (НХЛ), представляющие собой гетерогенную группу опухолей из лимфоидной ткани, наиболее часто (>90%) имеют В-клеточное происхождение. Возможно, этот факт обусловлен особенностями В- клеточного иммунного ответа. Так, необходимое поразительное разнообразие иммуноглобулинов (Ig) по специфичности центров связывания с антигеном обеспечивается различными механизмами, включающими соматический мутагенез, генную конверсию, рекомбинацию ряда генных сегментов, образующих полный V-ген (вариабельной области молекулы Ig).
Список литературы
1. <div><p>Ройт А., Бростофф Дж., Мейл Д. Иммунология. М.: Мир, 2000.</p><p>Sanchez-Beato M., Sanchez-Aguilera A., Piris M. Cell cycle deregulation in B cell lymphomas. Blood 2003;101:1220-35</p><p>Isaacson P., Du M. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-53</p><p>Falzon M., Isaacson P. The natural history of benign lymphoepithelial lesion of the salivary gland in which there is a monoclonal population of B cells. Am J Surg Pathol 1991;15:59-65</p><p>Isaacson P., Wright D. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984;53:2515-24</p><p>Adamson T., Fox R., Frisman D. et al. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. J Immunol 1983;130:203-8</p><p>Larsson A., Bredberg A., Henriksson G. et al. Immunohistochemistry of the B-cell component in lower lip salivary glands of Sjogrens syndrome and healthy subjects. Scand J Immunol 2005;61:98-107</p><p>Xanthou G., Tapinos N., Polihronis M. et al. CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjogrens syndrome. Clin Exp Immunol 1999;118:154-63</p><p>Tsunawaki S., Nakamura S., Ohyama Y. et al. Possible function of salivary gland epithelial cells as nonprofessional antigenpresenting cells in the development of Sjogrens syndrome. J Rheumatol 2002;29:1884-96</p><p>Dimitrou I., Kapsogeorgou E., Moutsopoulos H. et al. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjogrens syndrome patients indicating their intrinsic activation. Clin Exp Immunol 2002;127:386-92</p><p>Ittah M., Miceli-Richard C., Gottenberg J. et al. B-cell activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogrens syndrome. Arthr Res Ther 2006;8:51</p><p>Xanthou G., Polihronis M., Tzioufas A. et al. Lymphoid chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjogrens syndrome patients. Possible participation in lymphoid structure formation. Arthr Rheum 2001;44:408-18</p><p>Salomonsson S., Larsson P., Tengner P. et al. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogrens syndrome. Scand J Immunol 2002;55:336-42</p><p>Salomonsson S., Larsson P., Tengner P. et al. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjogrens syndrome. Scand J Immunol 2002;55:336-42</p><p>Barone F., Bombardieri M., Manzo A. et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogrens syndrome. Arthr Rheum 2005;52:1773-84</p><p>Vogelsang P., Jonsson M., Dalvin S. et al. Role of dendritic cells in Sjogrens syndrome. Scand J Immunol 2006;64:219-26</p><p>Lavie F., Miceli-Richard C., Quillard J. et al. Expression of BAFF (BLys) in T cell infiltrating labial salivary glands from patients with Sjogrens syndrome. J Pathol 2004;202:496-502</p><p>Stott D., Hiepe F., Hummel M. et al. Antigendriven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogrens syndrome. J Clin Invest 1998;102:938-46</p><p>Amft N., Curnow S., Scheel-Toellner D. et al. Ectopic expression of the B cellattracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogrens syndrome. Arthr Rheum 2001;44:2633-41</p><p>Salomonsson S., Jonsson M., Skarstein K. et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogrens syndrome. Arthr Rheum 2003;48:3187-201</p><p>Jonsson M., Szodoray P., Jellestad S. et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogrens syndrome. J Clin Immunol 2005;25:189-201</p><p>Cupedo T., Mebius R. Role of chemokines in the development of secondary and tertiary lymphoid tissues. Semin Immunol 2003;15:243-8</p><p>Schroder A., Greiner A., Seyfert C. et al. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci USA 1996;93:221-5</p><p>Nakajima K., Itoh K., Nagatani K. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007;36:365-72</p><p>Ziff M. Relation of cellular infiltration of rheumatoid synovial membrane to its immune response. Arthr Rheum 1974;17:313-9</p><p>Randen I., Mellbye O., Fёrre F. et al. The identification of germinal centres and follicular dendritic networks in rheumatoid synovial tissue. Scand J Immunol 1995;41:481-6</p><p>Nanki T., Hayashida K., El-Gabalawy H. et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4- T cell accumulation in rheumatoid arthritis synovium. J Immunol 2000;165:6590-8</p><p>Shi K., Hayashida K., Kaneko M. et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001;166:650-5</p><p>Weyand C., Kurtin P., Goronzy J. Ectopic lymphoid organogenesis. A fast track for autoimmunity. Am J Pathol 2001;159:787-93</p><p>Blades M., Ingegnoli F., Wheller S. et al. Stromal cell-derived factor 1 (CXCL12) induces monocyte migration into human synovium transplanted onto SCID mice. Arthr Rheum 2002;46:824-36</p><p>Sutherland A., Mackay F., Mackay C. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 2006;112:774-86</p><p>Dorner T., Putterman C. B cells, BAFF/zTNF4, TACI, and systemic lupus erythematosus. Arthr Res 2001;3:197-9</p><p>Ohata J., Zvaifler N., Nishio M. et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005;174:864-70</p><p>Cheema G., Roschke V., Hilbert D. et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immunebased rheumatic diseases. Arthr Rheum 2001;44:1313-9</p><p>Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep 2002;4:345-50</p><p>Groom J., Kalled S., Cutler A. et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109:59-68</p><p>Mariette X., Roux S., Zhang J. et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71</p><p>Szodoray P., Jellestad S., Alex P. et al. Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjogren's syndrome with special emphasis on BAFF. J Clin Immunol 2004;24:600-11</p><p>Daridon C., Devauchelle V., Hutin P. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthr Rheum 2007;56:1134-44</p><p>Ng L., Ng C., Woehl B. et al. BAFF costimulation of Toll-like receptor activated B-1 cells. Eur J Immunol 2006;36:1837-46.</p><p>Mackay F., Woodcock S., Lawton P. et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710</p><p>Rahman Z., Rao S., Kalled S. et al. Normal induction but also progression of germinal center responses in BAFF and BAFF-R deficient mice. J Exp Med 2003;198:1157-69</p><p>Vora K., Wang L., Rao S. et al. Cutting edge: germinal centers in the absence of B cell-activating factor belonging to the TNF family are impaired maturation and function. J Immunol 2003;171:547-51</p><p>Do R., Hatada E., Lee H. et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000;192:953-64</p><p>Liu H., Pope R. Apoptosis in rheumatoid arthritis: friend or foe. Rheum Dis Clin North Am 2004;30:603-25</p><p>Nagy G., Koncz A., Perl A. T- and Bcell abnormalities in systemic lupus erythematosus. Crit Rev Immunol 2005;25:123-40</p><p>Novak A., Grote D., Stenson M. et al. Expression of BLyS and its receptors in Bcell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004;104:2247-53</p><p>He B., Chadburn A., Jou E. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-79</p><p>Shinozaki K., Yasui K., Agematsu K. Direct B/B-cell interactions in immunoglobulin synthesis. Clin Exp Immunol 2001;124:386-91</p><p>Bohnhorst J., Bjorgan M., Thoen J. et al. Bm1-bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogrens syndrome. J Immunol 2001;167:3610-8</p><p>Bohnhorst J., Bjorgan M., Thoen J. et al. Abnormal B cell differentiation in primary Sjogrens syndrome results in a depressed percentage of circulating memory B cells and elevated levels of soluble CD27 that correlate with serum IgG concentration. Clin Immunol 2002;103:79-88</p><p>Hansen A., Odendahl M., Reiter K. et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjogrens syndrome. Arthr Rheum 2002;46:2160-7</p><p>Hansen A., Odendahl M., Reiter K. et al. Evidence for the migration and accumulation of memory B cells in the salivary glands of patients with Sjogrens syndrome. Arthr Rheum 2002;46:2160-71</p><p>Tangye S., Liu Y., Aversa G. et al. Identification of functional human memory B cells by expression CD 148 and CD27. J Exp Med 1998;188:1691-703</p><p>Do rner T., Lipsky P. Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjogrens syndrome. Arthr Res 2002;4:360-71</p><p>Lens S., Tesselaar K., van Oers M. et al. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998;10:491-9</p><p>Van Oers M., Pals S., Evers L. et al. Expression and release of CD27 in human B-cell malignancies. Blood 1993;82:3430-6</p><p>Jacobi A., Hansen A., Kaufmann O. et al. Analysis of immunglobulin light chain rearrangements in the salivary gland and blood of a patient with Sjogren's syndrome. Arthr Res 2002;4:4</p><p>Hansen A., Jacobi A., Pruss A. et al. Comparison of immunoglobulin heavy chain rearrangements between peripheral and glandular B cells in a patient with primary Sjogren's syndrome. Scand J Immunol 2003;57:470-</p><p>Deacon E., Matthews J., Potts A. et al. Expression of rheumatoid factor associated crossreactive idiotypes by glandular B cells in Sjogren's syndrome. Clin Exp Immunol 1991;83:280-5</p><p>Kipps T., Tomhave E., Chen P. et al. Molecular characterization of a major autoantibody-associated cross-reactive idiotype in Sjogrens syndrome. J Immunol 1989;142:4261-</p><p>Miklos J., Swerdlow S., Bahler D. Salivary gland mucosa associated lymphoid tissue lymphoma immunoglobulin VH genes show frequent use of V1-69 with distinctive CDR3 features. Blood 2000;95:3878-84</p><p>Martin T., Weber J., Levallois H. et al. Salivary gland lymphomas in patients with Sjogrens syndrome may frequently develop from rheumatoid factor B cells. Arthr Rheum 2000;43:908-16</p><p>Hansen A., Reiter K., Pruss A. et al. Dissemination of a Sjogrens syndromeassociated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutational pattern of nodal Ig heavy and light chain variable-region gene rearrangements. Arthr Rheum 2006;54:127-37</p><p>Pileri P., Uematsu Y., Campagnoli S. et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41</p><p>Quinn E., Chan C., Hadlock K. et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin's lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001;98:3745-9</p><p>Agnello V., Abel G., Elfahal M. et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766-71</p><p>De Re V., De Vita S., Marzotto A. et al. Pre-malignant and malignant lymphoproliferation in an HCV-ifected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer 2000;87:211</p><p>Sansonno D., De Vita S., Iacobelli A. et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998;160:3594-601</p><p>Vallat L., Benhamou Y., Gutierrez M. et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthr Rheum 2004;50:3668-78</p><p>Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 1997;19:111-29</p><p>Mazzaro C., Franzin F., Tulissi P. et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to interferon therapy. Cancer 1996;77:2604-13</p><p>Casato M., Agnello V., Pucillo L. et al. Predictors of long-term response to highdose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90:3865-73</p><p>He-Bin Fan, You-Fu Zhu, An-Shen Chen. B-cell clonality in the liver of hepatitis C virus-infected patients. World J Gastroenterol 2009;15:1636-40</p><p>Sansonno D., Lauletta G., De Re V. et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 2004;34:126-36</p><p>Gorevic, P., Frangione B. Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferative diseases. Semin Hematol 1991;28:79-94.</p><p>Knight G., Agnello V., Bonagura V. et al. Human rheumatoid factor cross-idiotypes. IV. Studies on WA XId-positive IgM without rheumatoid factor activity provide evidence that the WA XId is not unique to rheumatoid factors and is distinct from the 17.109 and G6 XIds. J Exp Med 1993;178:1903-11</p><p>De Re V., De Vita S., Marzotto A. et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 2000;96:3578-84</p><p>Ivanovski M., Silvestri F., Pozzato G. et al. Somatic hypermutation, clonal diversity, and preferential expression of the V51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998;91:2433-42</p><p>Marasca R., Vaccari P., Luppi M. et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001;159:253-61</p><p>Luppi M., Ferrari M., Bonaccorsi G. et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia 1996;10:351-5</p><p>Pal S., Sullivan D., Kim S. et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 2006;130:1107-16</p><p>Sansonno D., De Vita S., Cornachiulo V. et al. Detection and distribution of hepatitis C virus-related proteins in lymph nodes of patients with type II mixed cryoglobulinemia and neoplastic or nonneoplastic lymphoproliferation. Blood 1996;88:4638-45</p><p>Ray R., Meyer K., Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996;226:176-82</p><p>Ray R., Steele R., Meyer K. et al. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997;272:10983-6.</p><p>Zhu N., Khoshnan A., Schneider R. et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNFinduced apoptosis. J Virol 1998;72:3691-7</p><p>Marusawa H., Hijkata M., Chiba T. et al. Hepatitis C virus core protein inhibits Fas and tumor necrosis factor alpha-mediated apoptosis via NF-κB activation. J Virol 1999;73:4713-20</p><p>Kitay-Cohen Y., Amiel A., Hilzenrat N. et al. Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood 2000;96:2910-2</p><p>Zignego A., Ferri C., Giannelli F. et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002;137:571-80</p><p>Giannelli F., Moscarella S., Giannini C. et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003;102:1196-201.</p><p>Zignego A., Giannelli F., Marrocchi M. et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 2000;31:474-9</p><p>Sasso E., Martinez M., Yarfitz S. et al. Frequent joining of Bcl-2 to a JH6 gene in hepatitis C virus-associated t(14; 18). J Immunol 2004;173:3549-56</p><p>Fabris M., Quartuccio L., Sacco S. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology 2007;46:37-43</p><p>Sene D., Limal N., Ghillani-Dalbin P. Hepatitis C virus-associated B-cell proliferation - the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford) 2007;46:65-9</p><p>Landau D., Rosenzwajg M., Saadoun D. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Ann Rheum Dis 2009;68:337-44. 96. Cheema G., Roschke V., Hilbert D. et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immunebased rheumatic diseases. Arthr Rheum 2001;44:1313-9</p><p>Sansonno D., Carbone A., De Re V. et al. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology 2007;46:572-8.</p><p>Hansen A., Lipsky P., Do rner T. B-cell lymphoproliferation in chronic inflammatory rheumatic diseases. Nat Clin Pract Rheumatology 2007;10:561-9</p><p>Isaacson P., Du M. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-53.</p><p>De Re V., De Vita S., Gasparotto D. Salivary gland B cell lymphoproliferative disorders in Sjogren's syndrome present a restricted use of antigen receptor gene segments similar to those used by hepatitis C virus-associated non-Hodgkins's lymphomas. Eur J Immunol 2002;32:903-10</p><p>Ramos-Casals M., De Vita S., Tzioufas A. Hepatitis C virus, Sjogrens syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun Rev 2005;4:8-15</p><p>De Vita S., Zagonel V., Russo A. et al. Hepatitis C virus, non-Hodgkin's lymphomas and hepatocellular carcinoma. Br J Cancer 1998;77:2032-5.</p><p>Zintzaras E., Voulgarelis M., Moutsopoulos H. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44</p><p>Kauppi M., Pukkala E., Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997;8:201-4.</p><p>Smedby K., Hjalgrim H., Askling J. et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006;98:51-60</p><p>Kassan S., Thomas T., Moutsopoulos H. et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.</p><p>Valesini G., Priori R., Bavoillot D. et al. Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome. J Rheumatol 1997;24:2376-80.</p><p>Davidson B., Kelly C., Griffiths I. Primary Sjogren's syndrome in the northeast of England: a long-term follow-up study. Rheumatology (Oxford) 1999;38:245-53</p><p>Pertovaara M., Pukkala E., Laippala P. et al. A longitudinal cohort study of Finnish patients with primary Sjogren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 2001;60:467-72</p><p>Theander E., Henriksson G., Ljungberg O. et al. Lymphoma and other malignancies in primary Sjogren's syndrome. A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006;65:796-803</p><p>Engels E., Cerhan J., Linet M. et al. Immune-related conditions and immunemodulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 2005;162:1153-61</p><p>Fox R., Koh K., Saito I. Lymphoproliferative disorders in Sjogrens syndrome. In: Homma M., Sugai S., Tojo T. et al. (eds). Sjogrens syndrome. State of the Art. Amsterdam: Kugler, 1994;199-203</p><p>Ioannidis J., Vassiliou V., Moutsopoulos H. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogrens syndrome. Arthr Rheum 2002;46:741-7</p><p>Masaki Y., Sugai S. Lymphoproliferative disorders in Sjogrens syndrome. Autoimmun Rev 2004;3:175-82</p><p>Scopouli F., Dafni U., Ioannidis J. et al. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthr Rheum 2000;29:296-304</p><p>Stewart A., Blenkinsopp P., Henry K. Bilateral parotid MALT lymphoma and Sjogren's syndrome. Br J Oral Maxillofac Surg 1994;32:318-22</p><p>Sugai S., Shimizu S., Konda S. Lymphoproliferative disorders in Japanese patients with Sjogrens syndrome. Scand J Rheumatol 1986;61(Suppl.):118-22</p><p>Bjornadal L., Lofstrom B., Yin L. et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002;31:66-71</p><p>Bernatsky S., Boivin J., Joseph L. et al. An international cohort study of cancer in systemic lupus erythematosus. Arthr Rheum 2005;52:1481-90.</p><p>Vineis P., Crosignani P., Sacerdote C. et al. Haematopoietic cancer and medical history: a multicentre case control study. J Epidemiol Community Health 2000;54:431-6.</p><p>Pettersson T., Pukkala E., Teppo L. et al. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:437-9</p><p>Abu-Shakra M., Gladman D., Urowitz M. Malignancy in systemic lupus erythematosus. Arthr Rheum 1996;39:1050-4</p><p>Mellemkjaer L., Andersen V., Linet M. et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthr Rheum 1997;40:761-8</p><p>Sweeney D., Manzi S., Janosky J. et al. Risk of malignancy in women with systemic lupus erythematosus. J Rheumatol 1995;22:1478-82</p><p>Cibere J., Sibley J., Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001;10:394-400</p><p>Tarr T., Gyorfy B., Szekanecz E. Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center. Ann N Y Acad Sci 2007;1108:76-82</p><p>Szekanecz E., Szamosi S., Gergely L. Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis. Clin Rheumatol 2008;27:1163-6</p><p>Mellemkjaer L., Pfeiffer R., Engels E. et al. Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthr Rheum 2008;58:657-66</p><p>Chatterjee S., Dombi G., Severson R. Risk of malignancy in scleroderma. A populationbased cohort study. Arthr Rheum 2005;52:2415-24</p><p>Hill C., Nguyen A., Roder D. et al. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003;62:728-31</p><p>Smedby K., Claire M., Falster M. Autoimmune disorders and risk of non-odgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-38</p><p>Andras C., Ponyi A., Constantin T. et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008;35:438-44</p><p>Hill C., Zhang Y., Sigurgeirsson B. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a populationbased study. Lancet 2001;357:96-100</p><p>Zantos D., Zhang Y., Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21:1855-9</p><p>Buchbinder R., Forbes A., Hall S. et al. Incidence of malignant disease in biopsyproven inflammatory myopathy. A populationbased cohort study. Ann Intern Med 2001;134:1087-95</p><p>Sigurgeirsson B., Lindelof B., Edhag O. et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363-7</p><p>Stockton D., Doherty V., Brewster D. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001;85:41-5.</p><p>Hakulinen T., Isomaki H., Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985;78:29-32.</p><p>Mellemkjaer L., Linet M., Gridley G. et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.</p><p>Ekstrom K., Hjalgrim H., Brandt L. et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthr Rheum 2003;48:963-70</p><p>Gridley G., McLaughlin J., Ekbom A. et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.</p><p>Hemminki K., Li X., Sundquist K. et al. Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology 2008;47:698-701.</p><p>Tavani A., La Vecchia C., Franceschi S. et al. Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. Eur J Cancer Prev 2000;9:59-64.</p><p>Smitten A., Simon T., Hochberg M. et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthr Res Ther 2008;10:45</p><p>Kojima M., Nakamura S., Futamura N. et al. Malignant lymphoma in patients with rheumatic diseases other than Sjogren's syndrome: a clinicopathologic study of five cases and review of the Japanese literature. Jap J Clin Oncol 1997;27:84-90.</p><p>Baecklund E., Iliadou A., Askling J. et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthr Rheum 2006;54:692-701</p><p>Mariette X., Cazals-Hatem D., Warszawki J. et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-15. 148. Hoshida Y., Tomita Y., Zhiming D. et al. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and EpsteinBarr virus infection. Int J Cancer 2004;108:443-9.</p><p>Baecklund E., Backlin C., Iliadou A. et al. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthr Rheum 2006;54:3774-81</p><p>Kamel O., van de Rijn M., LeBrun D. et al. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994;25:638-43</p><p>Baecklund E., Sundstro m C., Ekbom A. et al. Lymphoma subtypes in patients with rheumatoid arthritis. Increased proportion of diffuse large B cell lymphoma. Arthr Rheum 2003;48:1543-50</p><p>Samanta A., Grant I., Nichol F. et al. Large granular lymphocytosis associated with rheumatoid arthritis. Ann Rheum Dis 1988;47:873-5.</p><p>Newland A., Catovsky D., Linch D. et al. Chronic T cell lymphocytosis: a review of 21 cases. Br J Haematol 1984;58:433-46.</p><p>Barton J.C., Prasthofer E., Egan M. et. al. Rheumatoid arthritis associated with expanded populations of granular lymphocytes. Ann Intern Med 1986;104:314-23</p><p>Lamy T., Loughran T. Large granular lymphocyte leukemia. Cancer Control 1998;5:25-33</p><p>Rose M., Berliner N. T-cell large granular lymphocyte leukemia and related disorders. Oncologist 2004;9:247-58</p><p>Loughran T. Clonal diseases of large granular lymphocytes. Blood 1993;82:1-14</p><p>Dhodapkar M., Li C., Lust J. et al. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significanceBlood 1994;84:1620-7</p><p>Loughran T., Starkebaum G., Kidd P. et al. Clonal proliferation of large granular lymphocytes in rheumatoid arthritis. Arthr Rheum 1988;31:31-6.</p><p>Freimark B., Lanier L., Phillips J. et al. Comparison of T cell receptor gene rearrangements in patients with large granular T cell leukemia and Felty's syndrome. J Immunol 1987;138:1724-9.</p><p>Harris N., Jaffe E., Diebold J. et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999;10:1419-32</p><p>largKe granular lymphocyte proliferation in rheumatoid arthritis. Rheumatol Int 1994;14:163-8.</p><p>Zenibayashi M., Saigo K., Chayahara N. et al. Gamma/delta T-cell receptor type granular lymphocyte proliferative disorder associated with rheumatoid arthritis. J Int Med Res 2005;33:583-9.</p><p>Brito-Zeron P., Ramos-Casals M., Bove A. et al. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 2007;46:1359-62</p><p>Tzioufas A., Boumba D., Scopouli F. et al. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor crossreactive idiotypes as predictive factors for the development of lymphoma in primary Sjogrens syndrome. Arthr Rheum 1996;39:767-72.</p><p>Anaya J., Mc-uff H., Banks P. et al. Clinicopathological factors relating malignant lymphoma with Sjogrens syndrome. Semin. Arthr Rheum 1996;25:337-46</p><p>Васильев В.И., Пробатова Н.А., Варламова Е.Ю. и др. Прогностическое значение смешанной моноклональной криоглобулинемии при болезни Шёгрена. Тер арх 2004;8:61-8.</p><p>Baecklund E., Ekbom A., Sparen P. et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. Br Med J 1998;317:180-1. 169. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkin's lymphoma in rheumatoid arhtritis: a 25 year study of 1,767 RA patients. Arthr Rheum 1998;41(Suppl. 9):188.</p><p>Walters M., Stevenson F., Herbert A. et al. Urinary monoclonal free light chains in primary Sjogrens syndrome: an aid to the diagnosis of malignant lymphoma. Ann Rheum Dis 1986;45:210-9.</p><p>Sugai S., Shimizu S., Konda S. et al. Lymphoproliferative disorders in Japanese patients with Sjogrens syndrome. In: Talal N., 82 Kassan S. (eds). Sjogrens syndrome: clinical and immunological aspects. Berlin: Springer Verlag 1987;144-6</p><p>Royer B., Cazals-Hatem D., Sibilia J. et al. Lymphomas in patients with Sjogrens syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997;90:766-75</p><p>Lofstrom B., Backlin C., Sundstrom C. et al. A closer look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 2007;66:1627-32</p><p>Ramsey-Goldman R., Mattai S., Schilling E. et al. Increased risk of malignancy in patients with systemic lupus erythematosus. J Investig Med 1998;46: 217-22</p><p>Bernatsky S., Joseph L., Boivin J. et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008;67:74-9.</p><p>Buchbinder R., Barber M., Heuzenroeder L. et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthr Rheum 2008;59:794-9</p><p>Matteson E., Hickey A., Maguire L. et al. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 1991;18:809-14</p><p>Jones M., Symmons D., Finn J. et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritisA matched cohort study. Br J Rheumatol 1996;35:738-45</p><p>Salloum E., Cooper D., Howe G. et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943-9</p><p>Mariette X., Cazals-Hatem D., Warszawki J. et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2002;99:3909-15.</p><p>Kamel O., Van de Rijn M., Weiss L. et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. New Engl J Med 1993;328:1317-31</p><p>Hoshida Y., Xu J., Fujita S. et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 2007;34:322-31</p><p>Askling J., Fored C., Baecklund E. et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20</p><p>Wolfe F., Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthr Rheum 2007;56:2886-95</p><p>Setoguchi S., Solomon D., Weinblatt M. et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthr Rheum 2006;54:2757-64.</p><p>Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthr Rheum 2004;50:1740-51</p><p>Morton L., Engels E., Holford T. et al. Hepatitis C virus of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev 2004;13:425-30</p><p>Mele A., Pulsoni A., Bianco E. et al. Hepatitis C virus and B-cell non-Hodgkin lymphoma: an Italian multicenter case-control study. Blood 2003;102:996-9</p><p>Luppi M., Longo G., Ferrari M. et al. Clinico-pathological characterization of hepatitis C virus-related B-cell non-odgkin's lymphomas without symptomatic cryoglobulinemia. Ann Oncol 1998;9:495-8</p><p>Gisbert J., Garcia-Buey L., Pajares J. et al. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology 2003;125:1723-32.</p><p>Matsuo K., Kusano A., Sugumar A. et al. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95:745-5</p><p>Zuckerman E., Zuckerman T. Hepatitis C and B-cell lymphoma: the hematohepatologist linkage. Blood Rev 2002;16:119-25</p><p>Arcaini L., Burcheri S., Rossi A. et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol 2007;18:346-50</p><p>Trejo O., Ramos-Casals M., Lopez Guillermo A. et al. Hematologic malignancies in patients with cryoglobulinemia: association with autoimmune and chronic viral diseases. Semin Arthr Rheum 2003;33:19-28.</p><p>Pozzato G., Mazzaro C., Crovatto M. et al. Low-grade malignant lymphoma, hepatitis C virus nfection and mixed cryoglobulinemia. Blood 1994;84:3047-53</p><p>Ferri C., Sebastiani M., Giuggioli D. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthr Rheum 2004;33:355-74.</p><p>Invernizzi F., Galli M., Serino G. et al. Secondary and essential cryoglobulinemias. Frequency, nosological classification, and long-term follow-up. Acta Haematol 1983;70:73-82.</p><p>Monti G., Pioltelli P., Saccardo F. Incidence and characteristics of non-odgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005;165:101-</p><p>Silvestri F., Barillari G., Fanin R. Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin's lymphomas. Haematologica 1997;82:314-7.</p><p>Germanidis G., Haioun C., Dhumeaux D. et al. Hepatitis C virus infection, mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphoma. Hepatology 1999;30:822-3.</p><p>Cesana C., Barbarano L., Miqueleiz S. et al. Clinical characteristics and outcome of immunoglobulin M-related disorders. Clin Lymphoma 2005;5:261-4.</p><p>De Vita S., Sacco C., Sansonno D. et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 1997;90:776-82</p><p>Saadoun D., Sellam J., Ghillani-Dalbin P. Increased risks of lymphoma and death among patients with nonhepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006;166:2101-8</p><p>La Civita L., Zignego A., Monti M. et al. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthr Rheum 1995;38:1859-60.</p></div><br />
Рецензия
Для цитирования:
Логвиненко О.А., Васильев В.И. НЕХОДЖКИНСКИЕ ЛИМФОМЫ ПРИ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЯХ. Научно-практическая ревматология. 2011;49(5):71-82. https://doi.org/10.14412/1995-4484-2011-1464
For citation:
Logvinenko O.A., Vasil'ev V.I. NEKhODZhKINSKIE LIMFOMY PRI REVMATIChESKIKh ZABOLEVANIYaKh. Rheumatology Science and Practice. 2011;49(5):71-82. (In Russ.) https://doi.org/10.14412/1995-4484-2011-1464
Просмотров:
1086
Послать статью по эл. почте 